Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of nab-paclitaxel plus nintedanib versus nab-paclitaxel plus placebo in relapsed NSCLC adenocarcinoma
2016-000109-35Phase 2Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-small cell lung cancer adenocarcinoma (NSCLC) comparing nab-paclitaxel + nintedanib with nab-paclitaxel + placebo (2 arms). Started Mar 2017; status: terminated.
02
Drugs
nab-paclitaxelnintedanib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2016-000109-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000109-35.